Levetiracetam (CAS 102767-28-2)
QUICK LINKS
Levetiracetam is a compound utilized in neuroscience research to study its modulatory effects on neurotransmitter release. The primary research focus is on its binding to synaptic vesicle protein 2A (SV2A) in the brain, which is believed to contribute to its mechanism of action. Levetiracetam is also used in the exploration of epileptogenesis, the process by which a normal brain develops epilepsy, and in models of seizure activity where it helps to understand the pathways and modulation of synaptic transmission. Additionally, its impact on neural networks and the potential neuroprotective effects are of interest, particularly in studies related to synaptic plasticity and neuronal excitability. Researchers employ levetiracetam to gain insights into the regulation of ion channels and receptors that are involved in the propagation of electrical signals in the nervous system.
Levetiracetam (CAS 102767-28-2) References
- The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. | Lynch, BA., et al. 2004. Proc Natl Acad Sci U S A. 101: 9861-6. PMID: 15210974
- Effect of levetiracetam on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection. | Ueda, Y., et al. 2007. Brain Res. 1151: 55-61. PMID: 17408599
- Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. | De Smedt, T., et al. 2007. CNS Drug Rev. 13: 43-56. PMID: 17461889
- Therapeutic Drug Monitoring of Levetiracetam in Select Populations. | Jarvie, D. and Mahmoud, SH. 2018. J Pharm Pharm Sci. 21: 149s-176s. PMID: 30096051
- Mechanisms Underlying Aggressive Behavior Induced by Antiepileptic Drugs: Focus on Topiramate, Levetiracetam, and Perampanel. | Hansen, CC., et al. 2018. Behav Neurol. 2018: 2064027. PMID: 30581496
- Levetiracetam at the End of Life: A Case Report and Discussion. | Mohamudally, A. and Clark, K. 2020. J Palliat Med. 23: 995-997. PMID: 31603723
- Levetiracetam and Suicidality: A Case Report and Literature Review. | Esang, M., et al. 2020. Prim Care Companion CNS Disord. 22: PMID: 32731314
- Levetiracetam-Induced Hepatic Dysfunction. | Gayatri, P., et al. 2020. Neurol India. 68: 910-912. PMID: 32859841
- Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review. | Steinhoff, BJ., et al. 2021. Epilepsy Behav. 118: 107939. PMID: 33839453
- Levetiracetam as the first-line treatment for neonatal seizures: a systematic review and meta-analysis. | Hooper, RG., et al. 2021. Dev Med Child Neurol. 63: 1283-1293. PMID: 34124790
- Levetiracetam in lactation: How much is excreted into human breast milk? | Dinavitser, N., et al. 2022. Br J Clin Pharmacol. 88: 199-205. PMID: 34131926
- Levetiracetam for Seizure Prophylaxis in Neurocritical Care: A Systematic Review and Meta-analysis. | Fang, T., et al. 2022. Neurocrit Care. 36: 248-258. PMID: 34286461
- Levetiracetam, lamotrigine and carbamazepine: which monotherapy during pregnancy? | Mari, L., et al. 2022. Neurol Sci. 43: 1993-2001. PMID: 34468899
- The safety of rapid infusion levetiracetam: A systematic review. | Jense, A., et al. 2022. Pharmacotherapy. 42: 495-503. PMID: 35502462
- Levetiracetam-induced gingival hyperplasia. | James, J., et al. 2022. J Postgrad Med. 68: 168-169. PMID: 35848684
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Levetiracetam, 10 mg | sc-203103 | 10 mg | $92.00 | |||
Levetiracetam, 50 mg | sc-203103A | 50 mg | $351.00 |